Our group identified overexpression of EZH2 in the CD30+ anaplastic T cells in PCALCLs, and showed that targeting EZH2 catalytic activity exerts a direct antitumor cell effect and also promotes T-cell-mediated immunity at the tumor site, which has significant implications for treating cutaneous CD30+LPDs as well as transformed MF75. The gene discussed is TNFRSF8; the disease is neoplasm.